Imagine a tiny, smart switch implanted directly into a tumor. Instead of flooding the whole body with harsh chemicals, this device acts like a remote-controlled faucet, releasing medicine only where and when it is needed. It uses a special chemical 'key' to unlock the drug, making treatment much safer and more effective.
Current chemotherapy often requires systemic administration, leading to severe off-target effects and limiting the use of highly potent drugs. There is a need for a way to deliver high concentrations of drugs locally and temporally without damaging healthy tissue.
An 8-channel optimization platform and both planar and capillary iontronic pump designs for controlled drug release.
If you are a pharmaceutical company dealing with drugs too toxic for systemic use — this project developed an iontronic switch that enables local administration. This allows the use of highly potent drugs that were previously inapplicable due to cytotoxicity.
If you are a device manufacturer dealing with the need for precise drug timing — this project developed a programmable iontronic pump. It allows for discrete and continuous drug concentration profiles at the tumor site.
If you are a surgical equipment provider dealing with non-operable tumors — this project developed a system to shrink tumors in mouse models. This can potentially make previously non-operable tumors eligible for surgical resection.
Based on available project data, there is no specific pricing or unit cost mentioned for the bioSWITCH device.
The project has developed an 8-channel, well-plate compatible platform for optimization, but full industrial scale-up details are not yet provided.
Based on available project data, the consortium includes 3 SMEs and 3 universities to ensure translation to market, though specific licensing terms are not listed.
The project period runs from 2023-03-01 to 2027-02-28, with current goals focused on demonstrating efficacy in a xenograft pancreas cancer mouse model.
It is an implantable iontronic switch designed for local administration directly to the tumor site to avoid systemic administration.
The consortium is well-balanced for commercial translation, featuring a 43% industry ratio with 3 SMEs and 3 universities across 4 countries (AT, HU, NL, SE). This mix of academic research and small-business agility suggests a strong focus on moving the technology from the lab toward a marketable medical product.
Contact Linköpings Universitet in Sweden
Contact us to explore licensing opportunities for iontronic drug delivery.
